PandemieGrippaleV1, PascalFrancis, Corpus, bibRecord, 000065

Vaccination coverage against hepatitis A and B viruses, Streptococcus pneumoniae, seasonal flu, and A(H1N1)2009 pandemic influenza in HIV-infected patients

Identifieur interne : 000065 ( PascalFrancis/Corpus ); précédent : 000064; suivant : 000066

Vaccination coverage against hepatitis A and B viruses, Streptococcus pneumoniae, seasonal flu, and A(H1N1)2009 pandemic influenza in HIV-infected patients

Auteurs : Florent Valour ; Laurent Cotte ; Nicolas Voirin ; Matthieu Godinot ; Florence Ader ; Tristan Ferry ; Philippe Vanhems ; Christian Chidiac

Source :

Vaccine [ 0264-410X ] ; 2014.

RBID : Pascal:14-0190715

Descripteurs français

Pascal (Inist)
- Streptococcus B, Streptococcus pneumoniae, Virus grippal A, Virus immunodéficience humaine, Couverture vaccinale, Grippe A, SIDA, Virus hépatite B, Pneumococcie, Hépatite virale B, Hépatite virale A.

English descriptors

KwdEn :
- AIDS, Hepatitis B virus, Human immunodeficiency virus, Influenza A, Influenza A virus, Pneumococcal infection, Streptococcus B, Streptococcus pneumoniae, Vaccination coverage, Viral hepatitis A, Viral hepatitis B.

Abstract

Background: Several vaccines are recommended in HIV-infected patients due to an increased risk of vaccine-preventable infections, severe forms of the disease, or shared transmission routes. Few data are available regarding vaccination coverage and its determinants in this population. Methods: A cross-sectional study was performed in HIV-infected patients included in a hospital-based cohort in 2011. Vaccination coverage against hepatitis A virus (HAV), hepatitis B virus (HBV), seasonal and A(H1N1)2009 pandemic influenza, and invasive pneumococcal diseases (IPD) were recorded. Factors associated with vaccination were assessed by multivariate logistic regression. Results: 2467 patients were included (median age: 47 years; male gender 71.5%; men having sex with men (MSM): 43.9%; CDC stage C: 24.3%; HBV and/or hepatitis C virus co-infection: 14.4%). Median duration of HIV infection was 10 years and 93.1% of patients received combination antiretroviral therapy. At baseline, the median CD4 count was 527 cells/mm³ and HIV viral load was <50 copies/mL in 83.3% of cases. Vaccination coverage for HBV, HAV, seasonal influenza, A(H1N1)2009 pandemic influenza, and IPD were 61.9%, 47.4%, 30.9, 48.3%, and 64.6%, respectively. Factors independently associated with vaccination were a younger (HBV) or an older age (influenza), male gender (HBV, HAV), MSM (HBV), CD4 count >200/mm³ and HIV-RNA <50 copies/mL (IPD, influenza), longer duration of HIV infection (IPD, influenza), and follow-up by an experienced physician (HBV, IPD). Conclusions: Vaccination coverage remained insufficient for all vaccine-preventable infections investigated in this study. Determinants for vaccination were largely not evidence-based, and efforts should be focused on improving physicians' knowledge about guidelines.

Notice en format standard (ISO 2709)

Pour connaître la documentation sur le format Inist Standard.

A01	`01`	`1`		`@0 0264-410X`
A02	`01`			`@0 VACCDE`
A03		`1`		`@0 Vaccine`
A05				`@2 32`
A06				`@2 35`
A08	`01`	`1`	`ENG`	`@1 Vaccination coverage against hepatitis A and B viruses, Streptococcus pneumoniae, seasonal flu, and A(H1N1)2009 pandemic influenza in HIV-infected patients`
A11	`01`	`1`		`@1 VALOUR (Florent)`
A11	`02`	`1`		`@1 COTTE (Laurent)`
A11	`03`	`1`		`@1 VOIRIN (Nicolas)`
A11	`04`	`1`		`@1 GODINOT (Matthieu)`
A11	`05`	`1`		`@1 ADER (Florence)`
A11	`06`	`1`		`@1 FERRY (Tristan)`
A11	`07`	`1`		`@1 VANHEMS (Philippe)`
A11	`08`	`1`		`@1 CHIDIAC (Christian)`
A14	`01`			`@1 Infectious Diseases Department, Hospices Civils de Lyon @2 Lyon @3 FRA @Z 1 aut. @Z 2 aut. @Z 4 aut. @Z 5 aut. @Z 6 aut. @Z 8 aut.`
A14	`02`			`@1 INSERM U1111, International Center for Research in Infectiology @2 Lyon @3 FRA @Z 1 aut. @Z 5 aut. @Z 6 aut. @Z 8 aut.`
A14	`03`			`@1 Université Claude Bernard Lyon 1 @2 Lyon @3 FRA @Z 1 aut. @Z 3 aut. @Z 5 aut. @Z 6 aut. @Z 7 aut. @Z 8 aut.`
A14	`04`			`@1 INSERM U1052 @2 Lyon @3 FRA @Z 2 aut.`
A14	`05`			`@1 Department of Hygiene and Epidemiology, Hospices Civils de Lyon @2 Lyon @3 FRA @Z 3 aut. @Z 7 aut.`
A20				`@1 4558-4564`
A21				`@1 2014`
A23	`01`			`@0 ENG`
A43	`01`			`@1 INIST @2 20289 @5 354000150336410280`
A44				`@0 0000 @1 © 2014 INIST-CNRS. All rights reserved.`
A45				`@0 42 ref.`
A47	`01`	`1`		`@0 14-0190715`
A60				`@1 P`
A61				`@0 A`
A64	`01`	`1`		`@0 Vaccine`
A66	`01`			`@0 GBR`
C01	`01`		`ENG`	@0 Background: Several vaccines are recommended in HIV-infected patients due to an increased risk of vaccine-preventable infections, severe forms of the disease, or shared transmission routes. Few data are available regarding vaccination coverage and its determinants in this population. Methods: A cross-sectional study was performed in HIV-infected patients included in a hospital-based cohort in 2011. Vaccination coverage against hepatitis A virus (HAV), hepatitis B virus (HBV), seasonal and A(H1N1)2009 pandemic influenza, and invasive pneumococcal diseases (IPD) were recorded. Factors associated with vaccination were assessed by multivariate logistic regression. Results: 2467 patients were included (median age: 47 years; male gender 71.5%; men having sex with men (MSM): 43.9%; CDC stage C: 24.3%; HBV and/or hepatitis C virus co-infection: 14.4%). Median duration of HIV infection was 10 years and 93.1% of patients received combination antiretroviral therapy. At baseline, the median CD4 count was 527 cells/mm³ and HIV viral load was <50 copies/mL in 83.3% of cases. Vaccination coverage for HBV, HAV, seasonal influenza, A(H1N1)2009 pandemic influenza, and IPD were 61.9%, 47.4%, 30.9, 48.3%, and 64.6%, respectively. Factors independently associated with vaccination were a younger (HBV) or an older age (influenza), male gender (HBV, HAV), MSM (HBV), CD4 count >200/mm³ and HIV-RNA <50 copies/mL (IPD, influenza), longer duration of HIV infection (IPD, influenza), and follow-up by an experienced physician (HBV, IPD). Conclusions: Vaccination coverage remained insufficient for all vaccine-preventable infections investigated in this study. Determinants for vaccination were largely not evidence-based, and efforts should be focused on improving physicians' knowledge about guidelines.
C02	`01`	`X`		`@0 002A05F04`
C02	`02`	`X`		`@0 002B05C02G`
C02	`03`	`X`		`@0 002A05B15`
C03	`01`	`X`	`FRE`	`@0 Streptococcus B @2 NS @5 01`
C03	`01`	`X`	`ENG`	`@0 Streptococcus B @2 NS @5 01`
C03	`01`	`X`	`SPA`	`@0 Streptococcus B @2 NS @5 01`
C03	`02`	`X`	`FRE`	`@0 Streptococcus pneumoniae @2 NS @5 02`
C03	`02`	`X`	`ENG`	`@0 Streptococcus pneumoniae @2 NS @5 02`
C03	`02`	`X`	`SPA`	`@0 Streptococcus pneumoniae @2 NS @5 02`
C03	`03`	`X`	`FRE`	`@0 Virus grippal A @2 NW @5 03`
C03	`03`	`X`	`ENG`	`@0 Influenza A virus @2 NW @5 03`
C03	`03`	`X`	`SPA`	`@0 Influenza A virus @2 NW @5 03`
C03	`04`	`X`	`FRE`	`@0 Virus immunodéficience humaine @2 NW @5 04`
C03	`04`	`X`	`ENG`	`@0 Human immunodeficiency virus @2 NW @5 04`
C03	`04`	`X`	`SPA`	`@0 Human immunodeficiency virus @2 NW @5 04`
C03	`05`	`X`	`FRE`	`@0 Couverture vaccinale @5 05`
C03	`05`	`X`	`ENG`	`@0 Vaccination coverage @5 05`
C03	`05`	`X`	`SPA`	`@0 Cobertura de vacunación @5 05`
C03	`06`	`X`	`FRE`	`@0 Grippe A @5 06`
C03	`06`	`X`	`ENG`	`@0 Influenza A @5 06`
C03	`06`	`X`	`SPA`	`@0 Gripe A @5 06`
C03	`07`	`X`	`FRE`	`@0 SIDA @5 07`
C03	`07`	`X`	`ENG`	`@0 AIDS @5 07`
C03	`07`	`X`	`SPA`	`@0 SIDA @5 07`
C03	`08`	`X`	`FRE`	`@0 Virus hépatite B @2 NW @5 08`
C03	`08`	`X`	`ENG`	`@0 Hepatitis B virus @2 NW @5 08`
C03	`08`	`X`	`SPA`	`@0 Hepatitis B virus @2 NW @5 08`
C03	`09`	`X`	`FRE`	`@0 Pneumococcie @5 09`
C03	`09`	`X`	`ENG`	`@0 Pneumococcal infection @5 09`
C03	`09`	`X`	`SPA`	`@0 Neumococia @5 09`
C03	`10`	`X`	`FRE`	`@0 Hépatite virale B @5 14`
C03	`10`	`X`	`ENG`	`@0 Viral hepatitis B @5 14`
C03	`10`	`X`	`SPA`	`@0 Hepatitis vírica B @5 14`
C03	`11`	`X`	`FRE`	`@0 Hépatite virale A @5 15`
C03	`11`	`X`	`ENG`	`@0 Viral hepatitis A @5 15`
C03	`11`	`X`	`SPA`	`@0 Hepatitis vírica A @5 15`
C07	`01`	`X`	`FRE`	`@0 Streptococcaceae @2 NS`
C07	`01`	`X`	`ENG`	`@0 Streptococcaceae @2 NS`
C07	`01`	`X`	`SPA`	`@0 Streptococcaceae @2 NS`
C07	`02`	`X`	`FRE`	`@0 Micrococcales @2 NS`
C07	`02`	`X`	`ENG`	`@0 Micrococcales @2 NS`
C07	`02`	`X`	`SPA`	`@0 Micrococcales @2 NS`
C07	`03`	`X`	`FRE`	`@0 Bactérie`
C07	`03`	`X`	`ENG`	`@0 Bacteria`
C07	`03`	`X`	`SPA`	`@0 Bacteria`
C07	`04`	`X`	`FRE`	`@0 Influenzavirus A @2 NW`
C07	`04`	`X`	`ENG`	`@0 Influenzavirus A @2 NW`
C07	`04`	`X`	`SPA`	`@0 Influenzavirus A @2 NW`
C07	`05`	`X`	`FRE`	`@0 Orthomyxoviridae @2 NW`
C07	`05`	`X`	`ENG`	`@0 Orthomyxoviridae @2 NW`
C07	`05`	`X`	`SPA`	`@0 Orthomyxoviridae @2 NW`
C07	`06`	`X`	`FRE`	`@0 Virus @2 NW`
C07	`06`	`X`	`ENG`	`@0 Virus @2 NW`
C07	`06`	`X`	`SPA`	`@0 Virus @2 NW`
C07	`07`	`X`	`FRE`	`@0 Lentivirus @2 NW`
C07	`07`	`X`	`ENG`	`@0 Lentivirus @2 NW`
C07	`07`	`X`	`SPA`	`@0 Lentivirus @2 NW`
C07	`08`	`X`	`FRE`	`@0 Retroviridae @2 NW`
C07	`08`	`X`	`ENG`	`@0 Retroviridae @2 NW`
C07	`08`	`X`	`SPA`	`@0 Retroviridae @2 NW`
C07	`09`	`X`	`FRE`	`@0 Virose`
C07	`09`	`X`	`ENG`	`@0 Viral disease`
C07	`09`	`X`	`SPA`	`@0 Virosis`
C07	`10`	`X`	`FRE`	`@0 Infection`
C07	`10`	`X`	`ENG`	`@0 Infection`
C07	`10`	`X`	`SPA`	`@0 Infección`
C07	`11`	`X`	`FRE`	`@0 Orthohepadnavirus @2 NW`
C07	`11`	`X`	`ENG`	`@0 Orthohepadnavirus @2 NW`
C07	`11`	`X`	`SPA`	`@0 Orthohepadnavirus @2 NW`
C07	`12`	`X`	`FRE`	`@0 Hepadnaviridae @2 NW`
C07	`12`	`X`	`ENG`	`@0 Hepadnaviridae @2 NW`
C07	`12`	`X`	`SPA`	`@0 Hepadnaviridae @2 NW`
C07	`13`	`X`	`FRE`	`@0 Streptococcie`
C07	`13`	`X`	`ENG`	`@0 Streptococcal infection`
C07	`13`	`X`	`SPA`	`@0 Estreptococia`
C07	`14`	`X`	`FRE`	`@0 Bactériose`
C07	`14`	`X`	`ENG`	`@0 Bacteriosis`
C07	`14`	`X`	`SPA`	`@0 Bacteriosis`
C07	`15`	`X`	`FRE`	`@0 Pathologie de l'appareil digestif @5 13`
C07	`15`	`X`	`ENG`	`@0 Digestive diseases @5 13`
C07	`15`	`X`	`SPA`	`@0 Aparato digestivo patología @5 13`
C07	`16`	`X`	`FRE`	`@0 Pathologie du foie @5 16`
C07	`16`	`X`	`ENG`	`@0 Hepatic disease @5 16`
C07	`16`	`X`	`SPA`	`@0 Hígado patología @5 16`
C07	`17`	`X`	`FRE`	`@0 Immunodéficit @5 18`
C07	`17`	`X`	`ENG`	`@0 Immune deficiency @5 18`
C07	`17`	`X`	`SPA`	`@0 Inmunodeficiencia @5 18`
C07	`18`	`X`	`FRE`	`@0 Immunopathologie @5 19`
C07	`18`	`X`	`ENG`	`@0 Immunopathology @5 19`
C07	`18`	`X`	`SPA`	`@0 Inmunopatología @5 19`
N21				`@1 237`
N44	`01`			`@1 OTO`
N82				`@1 OTO`

Format Inist (serveur)

NO :	PASCAL 14-0190715 INIST
ET :	Vaccination coverage against hepatitis A and B viruses, Streptococcus pneumoniae, seasonal flu, and A(H1N1)2009 pandemic influenza in HIV-infected patients
AU :	VALOUR (Florent); COTTE (Laurent); VOIRIN (Nicolas); GODINOT (Matthieu); ADER (Florence); FERRY (Tristan); VANHEMS (Philippe); CHIDIAC (Christian)
AF :	Infectious Diseases Department, Hospices Civils de Lyon/Lyon/France (1 aut., 2 aut., 4 aut., 5 aut., 6 aut., 8 aut.); INSERM U1111, International Center for Research in Infectiology/Lyon/France (1 aut., 5 aut., 6 aut., 8 aut.); Université Claude Bernard Lyon 1/Lyon/France (1 aut., 3 aut., 5 aut., 6 aut., 7 aut., 8 aut.); INSERM U1052/Lyon/France (2 aut.); Department of Hygiene and Epidemiology, Hospices Civils de Lyon/Lyon/France (3 aut., 7 aut.)
DT :	Publication en série; Niveau analytique
SO :	Vaccine; ISSN 0264-410X; Coden VACCDE; Royaume-Uni; Da. 2014; Vol. 32; No. 35; Pp. 4558-4564; Bibl. 42 ref.
LA :	Anglais
EA :	Background: Several vaccines are recommended in HIV-infected patients due to an increased risk of vaccine-preventable infections, severe forms of the disease, or shared transmission routes. Few data are available regarding vaccination coverage and its determinants in this population. Methods: A cross-sectional study was performed in HIV-infected patients included in a hospital-based cohort in 2011. Vaccination coverage against hepatitis A virus (HAV), hepatitis B virus (HBV), seasonal and A(H1N1)2009 pandemic influenza, and invasive pneumococcal diseases (IPD) were recorded. Factors associated with vaccination were assessed by multivariate logistic regression. Results: 2467 patients were included (median age: 47 years; male gender 71.5%; men having sex with men (MSM): 43.9%; CDC stage C: 24.3%; HBV and/or hepatitis C virus co-infection: 14.4%). Median duration of HIV infection was 10 years and 93.1% of patients received combination antiretroviral therapy. At baseline, the median CD4 count was 527 cells/mm³ and HIV viral load was <50 copies/mL in 83.3% of cases. Vaccination coverage for HBV, HAV, seasonal influenza, A(H1N1)2009 pandemic influenza, and IPD were 61.9%, 47.4%, 30.9, 48.3%, and 64.6%, respectively. Factors independently associated with vaccination were a younger (HBV) or an older age (influenza), male gender (HBV, HAV), MSM (HBV), CD4 count >200/mm³ and HIV-RNA <50 copies/mL (IPD, influenza), longer duration of HIV infection (IPD, influenza), and follow-up by an experienced physician (HBV, IPD). Conclusions: Vaccination coverage remained insufficient for all vaccine-preventable infections investigated in this study. Determinants for vaccination were largely not evidence-based, and efforts should be focused on improving physicians' knowledge about guidelines.
CC :	002A05F04; 002B05C02G; 002A05B15
FD :	Streptococcus B; Streptococcus pneumoniae; Virus grippal A; Virus immunodéficience humaine; Couverture vaccinale; Grippe A; SIDA; Virus hépatite B; Pneumococcie; Hépatite virale B; Hépatite virale A
FG :	Streptococcaceae; Micrococcales; Bactérie; Influenzavirus A; Orthomyxoviridae; Virus; Lentivirus; Retroviridae; Virose; Infection; Orthohepadnavirus; Hepadnaviridae; Streptococcie; Bactériose; Pathologie de l'appareil digestif; Pathologie du foie; Immunodéficit; Immunopathologie
ED :	Streptococcus B; Streptococcus pneumoniae; Influenza A virus; Human immunodeficiency virus; Vaccination coverage; Influenza A; AIDS; Hepatitis B virus; Pneumococcal infection; Viral hepatitis B; Viral hepatitis A
EG :	Streptococcaceae; Micrococcales; Bacteria; Influenzavirus A; Orthomyxoviridae; Virus; Lentivirus; Retroviridae; Viral disease; Infection; Orthohepadnavirus; Hepadnaviridae; Streptococcal infection; Bacteriosis; Digestive diseases; Hepatic disease; Immune deficiency; Immunopathology
SD :	Streptococcus B; Streptococcus pneumoniae; Influenza A virus; Human immunodeficiency virus; Cobertura de vacunación; Gripe A; SIDA; Hepatitis B virus; Neumococia; Hepatitis vírica B; Hepatitis vírica A
LO :	INIST-20289.354000150336410280
ID :	14-0190715

Links to Exploration step

Pascal:14-0190715

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Vaccination coverage against hepatitis A and B viruses, Streptococcus pneumoniae, seasonal flu, and A(H1N1)2009 pandemic influenza in HIV-infected patients</title>
<author><name sortKey="Valour, Florent" sort="Valour, Florent" uniqKey="Valour F" first="Florent" last="Valour">Florent Valour</name>
<affiliation><inist:fA14 i1="01"><s1>Infectious Diseases Department, Hospices Civils de Lyon</s1>
<s2>Lyon</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="02"><s1>INSERM U1111, International Center for Research in Infectiology</s1>
<s2>Lyon</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="03"><s1>Université Claude Bernard Lyon 1</s1>
<s2>Lyon</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Cotte, Laurent" sort="Cotte, Laurent" uniqKey="Cotte L" first="Laurent" last="Cotte">Laurent Cotte</name>
<affiliation><inist:fA14 i1="01"><s1>Infectious Diseases Department, Hospices Civils de Lyon</s1>
<s2>Lyon</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="04"><s1>INSERM U1052</s1>
<s2>Lyon</s2>
<s3>FRA</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Voirin, Nicolas" sort="Voirin, Nicolas" uniqKey="Voirin N" first="Nicolas" last="Voirin">Nicolas Voirin</name>
<affiliation><inist:fA14 i1="03"><s1>Université Claude Bernard Lyon 1</s1>
<s2>Lyon</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="05"><s1>Department of Hygiene and Epidemiology, Hospices Civils de Lyon</s1>
<s2>Lyon</s2>
<s3>FRA</s3>
<sZ>3 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Godinot, Matthieu" sort="Godinot, Matthieu" uniqKey="Godinot M" first="Matthieu" last="Godinot">Matthieu Godinot</name>
<affiliation><inist:fA14 i1="01"><s1>Infectious Diseases Department, Hospices Civils de Lyon</s1>
<s2>Lyon</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Ader, Florence" sort="Ader, Florence" uniqKey="Ader F" first="Florence" last="Ader">Florence Ader</name>
<affiliation><inist:fA14 i1="01"><s1>Infectious Diseases Department, Hospices Civils de Lyon</s1>
<s2>Lyon</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="02"><s1>INSERM U1111, International Center for Research in Infectiology</s1>
<s2>Lyon</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="03"><s1>Université Claude Bernard Lyon 1</s1>
<s2>Lyon</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Ferry, Tristan" sort="Ferry, Tristan" uniqKey="Ferry T" first="Tristan" last="Ferry">Tristan Ferry</name>
<affiliation><inist:fA14 i1="01"><s1>Infectious Diseases Department, Hospices Civils de Lyon</s1>
<s2>Lyon</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="02"><s1>INSERM U1111, International Center for Research in Infectiology</s1>
<s2>Lyon</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="03"><s1>Université Claude Bernard Lyon 1</s1>
<s2>Lyon</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Vanhems, Philippe" sort="Vanhems, Philippe" uniqKey="Vanhems P" first="Philippe" last="Vanhems">Philippe Vanhems</name>
<affiliation><inist:fA14 i1="03"><s1>Université Claude Bernard Lyon 1</s1>
<s2>Lyon</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="05"><s1>Department of Hygiene and Epidemiology, Hospices Civils de Lyon</s1>
<s2>Lyon</s2>
<s3>FRA</s3>
<sZ>3 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Chidiac, Christian" sort="Chidiac, Christian" uniqKey="Chidiac C" first="Christian" last="Chidiac">Christian Chidiac</name>
<affiliation><inist:fA14 i1="01"><s1>Infectious Diseases Department, Hospices Civils de Lyon</s1>
<s2>Lyon</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="02"><s1>INSERM U1111, International Center for Research in Infectiology</s1>
<s2>Lyon</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="03"><s1>Université Claude Bernard Lyon 1</s1>
<s2>Lyon</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">14-0190715</idno>
<date when="2014">2014</date>
<idno type="stanalyst">PASCAL 14-0190715 INIST</idno>
<idno type="RBID">Pascal:14-0190715</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000065</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Vaccination coverage against hepatitis A and B viruses, Streptococcus pneumoniae, seasonal flu, and A(H1N1)2009 pandemic influenza in HIV-infected patients</title>
<author><name sortKey="Valour, Florent" sort="Valour, Florent" uniqKey="Valour F" first="Florent" last="Valour">Florent Valour</name>
<affiliation><inist:fA14 i1="01"><s1>Infectious Diseases Department, Hospices Civils de Lyon</s1>
<s2>Lyon</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="02"><s1>INSERM U1111, International Center for Research in Infectiology</s1>
<s2>Lyon</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="03"><s1>Université Claude Bernard Lyon 1</s1>
<s2>Lyon</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Cotte, Laurent" sort="Cotte, Laurent" uniqKey="Cotte L" first="Laurent" last="Cotte">Laurent Cotte</name>
<affiliation><inist:fA14 i1="01"><s1>Infectious Diseases Department, Hospices Civils de Lyon</s1>
<s2>Lyon</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="04"><s1>INSERM U1052</s1>
<s2>Lyon</s2>
<s3>FRA</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Voirin, Nicolas" sort="Voirin, Nicolas" uniqKey="Voirin N" first="Nicolas" last="Voirin">Nicolas Voirin</name>
<affiliation><inist:fA14 i1="03"><s1>Université Claude Bernard Lyon 1</s1>
<s2>Lyon</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="05"><s1>Department of Hygiene and Epidemiology, Hospices Civils de Lyon</s1>
<s2>Lyon</s2>
<s3>FRA</s3>
<sZ>3 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Godinot, Matthieu" sort="Godinot, Matthieu" uniqKey="Godinot M" first="Matthieu" last="Godinot">Matthieu Godinot</name>
<affiliation><inist:fA14 i1="01"><s1>Infectious Diseases Department, Hospices Civils de Lyon</s1>
<s2>Lyon</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Ader, Florence" sort="Ader, Florence" uniqKey="Ader F" first="Florence" last="Ader">Florence Ader</name>
<affiliation><inist:fA14 i1="01"><s1>Infectious Diseases Department, Hospices Civils de Lyon</s1>
<s2>Lyon</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="02"><s1>INSERM U1111, International Center for Research in Infectiology</s1>
<s2>Lyon</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="03"><s1>Université Claude Bernard Lyon 1</s1>
<s2>Lyon</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Ferry, Tristan" sort="Ferry, Tristan" uniqKey="Ferry T" first="Tristan" last="Ferry">Tristan Ferry</name>
<affiliation><inist:fA14 i1="01"><s1>Infectious Diseases Department, Hospices Civils de Lyon</s1>
<s2>Lyon</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="02"><s1>INSERM U1111, International Center for Research in Infectiology</s1>
<s2>Lyon</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="03"><s1>Université Claude Bernard Lyon 1</s1>
<s2>Lyon</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Vanhems, Philippe" sort="Vanhems, Philippe" uniqKey="Vanhems P" first="Philippe" last="Vanhems">Philippe Vanhems</name>
<affiliation><inist:fA14 i1="03"><s1>Université Claude Bernard Lyon 1</s1>
<s2>Lyon</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="05"><s1>Department of Hygiene and Epidemiology, Hospices Civils de Lyon</s1>
<s2>Lyon</s2>
<s3>FRA</s3>
<sZ>3 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Chidiac, Christian" sort="Chidiac, Christian" uniqKey="Chidiac C" first="Christian" last="Chidiac">Christian Chidiac</name>
<affiliation><inist:fA14 i1="01"><s1>Infectious Diseases Department, Hospices Civils de Lyon</s1>
<s2>Lyon</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="02"><s1>INSERM U1111, International Center for Research in Infectiology</s1>
<s2>Lyon</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="03"><s1>Université Claude Bernard Lyon 1</s1>
<s2>Lyon</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Vaccine</title>
<title level="j" type="abbreviated">Vaccine</title>
<idno type="ISSN">0264-410X</idno>
<imprint><date when="2014">2014</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Vaccine</title>
<title level="j" type="abbreviated">Vaccine</title>
<idno type="ISSN">0264-410X</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>AIDS</term>
<term>Hepatitis B virus</term>
<term>Human immunodeficiency virus</term>
<term>Influenza A</term>
<term>Influenza A virus</term>
<term>Pneumococcal infection</term>
<term>Streptococcus B</term>
<term>Streptococcus pneumoniae</term>
<term>Vaccination coverage</term>
<term>Viral hepatitis A</term>
<term>Viral hepatitis B</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Streptococcus B</term>
<term>Streptococcus pneumoniae</term>
<term>Virus grippal A</term>
<term>Virus immunodéficience humaine</term>
<term>Couverture vaccinale</term>
<term>Grippe A</term>
<term>SIDA</term>
<term>Virus hépatite B</term>
<term>Pneumococcie</term>
<term>Hépatite virale B</term>
<term>Hépatite virale A</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Background: Several vaccines are recommended in HIV-infected patients due to an increased risk of vaccine-preventable infections, severe forms of the disease, or shared transmission routes. Few data are available regarding vaccination coverage and its determinants in this population. Methods: A cross-sectional study was performed in HIV-infected patients included in a hospital-based cohort in 2011. Vaccination coverage against hepatitis A virus (HAV), hepatitis B virus (HBV), seasonal and A(H1N1)2009 pandemic influenza, and invasive pneumococcal diseases (IPD) were recorded. Factors associated with vaccination were assessed by multivariate logistic regression. Results: 2467 patients were included (median age: 47 years; male gender 71.5%; men having sex with men (MSM): 43.9%; CDC stage C: 24.3%; HBV and/or hepatitis C virus co-infection: 14.4%). Median duration of HIV infection was 10 years and 93.1% of patients received combination antiretroviral therapy. At baseline, the median CD4 count was 527 cells/mm<sup>3</sup>
 and HIV viral load was <50 copies/mL in 83.3% of cases. Vaccination coverage for HBV, HAV, seasonal influenza, A(H1N1)2009 pandemic influenza, and IPD were 61.9%, 47.4%, 30.9, 48.3%, and 64.6%, respectively. Factors independently associated with vaccination were a younger (HBV) or an older age (influenza), male gender (HBV, HAV), MSM (HBV), CD4 count >200/mm<sup>3</sup>
 and HIV-RNA <50 copies/mL (IPD, influenza), longer duration of HIV infection (IPD, influenza), and follow-up by an experienced physician (HBV, IPD). Conclusions: Vaccination coverage remained insufficient for all vaccine-preventable infections investigated in this study. Determinants for vaccination were largely not evidence-based, and efforts should be focused on improving physicians' knowledge about guidelines.</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0264-410X</s0>
</fA01>
<fA02 i1="01"><s0>VACCDE</s0>
</fA02>
<fA03 i2="1"><s0>Vaccine</s0>
</fA03>
<fA05><s2>32</s2>
</fA05>
<fA06><s2>35</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>Vaccination coverage against hepatitis A and B viruses, Streptococcus pneumoniae, seasonal flu, and A(H1N1)2009 pandemic influenza in HIV-infected patients</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>VALOUR (Florent)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>COTTE (Laurent)</s1>
</fA11>
<fA11 i1="03" i2="1"><s1>VOIRIN (Nicolas)</s1>
</fA11>
<fA11 i1="04" i2="1"><s1>GODINOT (Matthieu)</s1>
</fA11>
<fA11 i1="05" i2="1"><s1>ADER (Florence)</s1>
</fA11>
<fA11 i1="06" i2="1"><s1>FERRY (Tristan)</s1>
</fA11>
<fA11 i1="07" i2="1"><s1>VANHEMS (Philippe)</s1>
</fA11>
<fA11 i1="08" i2="1"><s1>CHIDIAC (Christian)</s1>
</fA11>
<fA14 i1="01"><s1>Infectious Diseases Department, Hospices Civils de Lyon</s1>
<s2>Lyon</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>8 aut.</sZ>
</fA14>
<fA14 i1="02"><s1>INSERM U1111, International Center for Research in Infectiology</s1>
<s2>Lyon</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>8 aut.</sZ>
</fA14>
<fA14 i1="03"><s1>Université Claude Bernard Lyon 1</s1>
<s2>Lyon</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
</fA14>
<fA14 i1="04"><s1>INSERM U1052</s1>
<s2>Lyon</s2>
<s3>FRA</s3>
<sZ>2 aut.</sZ>
</fA14>
<fA14 i1="05"><s1>Department of Hygiene and Epidemiology, Hospices Civils de Lyon</s1>
<s2>Lyon</s2>
<s3>FRA</s3>
<sZ>3 aut.</sZ>
<sZ>7 aut.</sZ>
</fA14>
<fA20><s1>4558-4564</s1>
</fA20>
<fA21><s1>2014</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>20289</s2>
<s5>354000150336410280</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 2014 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>42 ref.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>14-0190715</s0>
</fA47>
<fA60><s1>P</s1>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>Vaccine</s0>
</fA64>
<fA66 i1="01"><s0>GBR</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>Background: Several vaccines are recommended in HIV-infected patients due to an increased risk of vaccine-preventable infections, severe forms of the disease, or shared transmission routes. Few data are available regarding vaccination coverage and its determinants in this population. Methods: A cross-sectional study was performed in HIV-infected patients included in a hospital-based cohort in 2011. Vaccination coverage against hepatitis A virus (HAV), hepatitis B virus (HBV), seasonal and A(H1N1)2009 pandemic influenza, and invasive pneumococcal diseases (IPD) were recorded. Factors associated with vaccination were assessed by multivariate logistic regression. Results: 2467 patients were included (median age: 47 years; male gender 71.5%; men having sex with men (MSM): 43.9%; CDC stage C: 24.3%; HBV and/or hepatitis C virus co-infection: 14.4%). Median duration of HIV infection was 10 years and 93.1% of patients received combination antiretroviral therapy. At baseline, the median CD4 count was 527 cells/mm<sup>3</sup>
 and HIV viral load was <50 copies/mL in 83.3% of cases. Vaccination coverage for HBV, HAV, seasonal influenza, A(H1N1)2009 pandemic influenza, and IPD were 61.9%, 47.4%, 30.9, 48.3%, and 64.6%, respectively. Factors independently associated with vaccination were a younger (HBV) or an older age (influenza), male gender (HBV, HAV), MSM (HBV), CD4 count >200/mm<sup>3</sup>
 and HIV-RNA <50 copies/mL (IPD, influenza), longer duration of HIV infection (IPD, influenza), and follow-up by an experienced physician (HBV, IPD). Conclusions: Vaccination coverage remained insufficient for all vaccine-preventable infections investigated in this study. Determinants for vaccination were largely not evidence-based, and efforts should be focused on improving physicians' knowledge about guidelines.</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002A05F04</s0>
</fC02>
<fC02 i1="02" i2="X"><s0>002B05C02G</s0>
</fC02>
<fC02 i1="03" i2="X"><s0>002A05B15</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Streptococcus B</s0>
<s2>NS</s2>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Streptococcus B</s0>
<s2>NS</s2>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Streptococcus B</s0>
<s2>NS</s2>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Streptococcus pneumoniae</s0>
<s2>NS</s2>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Streptococcus pneumoniae</s0>
<s2>NS</s2>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Streptococcus pneumoniae</s0>
<s2>NS</s2>
<s5>02</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Virus grippal A</s0>
<s2>NW</s2>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Influenza A virus</s0>
<s2>NW</s2>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Influenza A virus</s0>
<s2>NW</s2>
<s5>03</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Virus immunodéficience humaine</s0>
<s2>NW</s2>
<s5>04</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Human immunodeficiency virus</s0>
<s2>NW</s2>
<s5>04</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Human immunodeficiency virus</s0>
<s2>NW</s2>
<s5>04</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>Couverture vaccinale</s0>
<s5>05</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>Vaccination coverage</s0>
<s5>05</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA"><s0>Cobertura de vacunación</s0>
<s5>05</s5>
</fC03>
<fC03 i1="06" i2="X" l="FRE"><s0>Grippe A</s0>
<s5>06</s5>
</fC03>
<fC03 i1="06" i2="X" l="ENG"><s0>Influenza A</s0>
<s5>06</s5>
</fC03>
<fC03 i1="06" i2="X" l="SPA"><s0>Gripe A</s0>
<s5>06</s5>
</fC03>
<fC03 i1="07" i2="X" l="FRE"><s0>SIDA</s0>
<s5>07</s5>
</fC03>
<fC03 i1="07" i2="X" l="ENG"><s0>AIDS</s0>
<s5>07</s5>
</fC03>
<fC03 i1="07" i2="X" l="SPA"><s0>SIDA</s0>
<s5>07</s5>
</fC03>
<fC03 i1="08" i2="X" l="FRE"><s0>Virus hépatite B</s0>
<s2>NW</s2>
<s5>08</s5>
</fC03>
<fC03 i1="08" i2="X" l="ENG"><s0>Hepatitis B virus</s0>
<s2>NW</s2>
<s5>08</s5>
</fC03>
<fC03 i1="08" i2="X" l="SPA"><s0>Hepatitis B virus</s0>
<s2>NW</s2>
<s5>08</s5>
</fC03>
<fC03 i1="09" i2="X" l="FRE"><s0>Pneumococcie</s0>
<s5>09</s5>
</fC03>
<fC03 i1="09" i2="X" l="ENG"><s0>Pneumococcal infection</s0>
<s5>09</s5>
</fC03>
<fC03 i1="09" i2="X" l="SPA"><s0>Neumococia</s0>
<s5>09</s5>
</fC03>
<fC03 i1="10" i2="X" l="FRE"><s0>Hépatite virale B</s0>
<s5>14</s5>
</fC03>
<fC03 i1="10" i2="X" l="ENG"><s0>Viral hepatitis B</s0>
<s5>14</s5>
</fC03>
<fC03 i1="10" i2="X" l="SPA"><s0>Hepatitis vírica B</s0>
<s5>14</s5>
</fC03>
<fC03 i1="11" i2="X" l="FRE"><s0>Hépatite virale A</s0>
<s5>15</s5>
</fC03>
<fC03 i1="11" i2="X" l="ENG"><s0>Viral hepatitis A</s0>
<s5>15</s5>
</fC03>
<fC03 i1="11" i2="X" l="SPA"><s0>Hepatitis vírica A</s0>
<s5>15</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Streptococcaceae</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Streptococcaceae</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Streptococcaceae</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Micrococcales</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>Micrococcales</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>Micrococcales</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="03" i2="X" l="FRE"><s0>Bactérie</s0>
</fC07>
<fC07 i1="03" i2="X" l="ENG"><s0>Bacteria</s0>
</fC07>
<fC07 i1="03" i2="X" l="SPA"><s0>Bacteria</s0>
</fC07>
<fC07 i1="04" i2="X" l="FRE"><s0>Influenzavirus A</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="04" i2="X" l="ENG"><s0>Influenzavirus A</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="04" i2="X" l="SPA"><s0>Influenzavirus A</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="05" i2="X" l="FRE"><s0>Orthomyxoviridae</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="05" i2="X" l="ENG"><s0>Orthomyxoviridae</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="05" i2="X" l="SPA"><s0>Orthomyxoviridae</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="06" i2="X" l="FRE"><s0>Virus</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="06" i2="X" l="ENG"><s0>Virus</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="06" i2="X" l="SPA"><s0>Virus</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="07" i2="X" l="FRE"><s0>Lentivirus</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="07" i2="X" l="ENG"><s0>Lentivirus</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="07" i2="X" l="SPA"><s0>Lentivirus</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="08" i2="X" l="FRE"><s0>Retroviridae</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="08" i2="X" l="ENG"><s0>Retroviridae</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="08" i2="X" l="SPA"><s0>Retroviridae</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="09" i2="X" l="FRE"><s0>Virose</s0>
</fC07>
<fC07 i1="09" i2="X" l="ENG"><s0>Viral disease</s0>
</fC07>
<fC07 i1="09" i2="X" l="SPA"><s0>Virosis</s0>
</fC07>
<fC07 i1="10" i2="X" l="FRE"><s0>Infection</s0>
</fC07>
<fC07 i1="10" i2="X" l="ENG"><s0>Infection</s0>
</fC07>
<fC07 i1="10" i2="X" l="SPA"><s0>Infección</s0>
</fC07>
<fC07 i1="11" i2="X" l="FRE"><s0>Orthohepadnavirus</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="11" i2="X" l="ENG"><s0>Orthohepadnavirus</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="11" i2="X" l="SPA"><s0>Orthohepadnavirus</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="12" i2="X" l="FRE"><s0>Hepadnaviridae</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="12" i2="X" l="ENG"><s0>Hepadnaviridae</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="12" i2="X" l="SPA"><s0>Hepadnaviridae</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="13" i2="X" l="FRE"><s0>Streptococcie</s0>
</fC07>
<fC07 i1="13" i2="X" l="ENG"><s0>Streptococcal infection</s0>
</fC07>
<fC07 i1="13" i2="X" l="SPA"><s0>Estreptococia</s0>
</fC07>
<fC07 i1="14" i2="X" l="FRE"><s0>Bactériose</s0>
</fC07>
<fC07 i1="14" i2="X" l="ENG"><s0>Bacteriosis</s0>
</fC07>
<fC07 i1="14" i2="X" l="SPA"><s0>Bacteriosis</s0>
</fC07>
<fC07 i1="15" i2="X" l="FRE"><s0>Pathologie de l'appareil digestif</s0>
<s5>13</s5>
</fC07>
<fC07 i1="15" i2="X" l="ENG"><s0>Digestive diseases</s0>
<s5>13</s5>
</fC07>
<fC07 i1="15" i2="X" l="SPA"><s0>Aparato digestivo patología</s0>
<s5>13</s5>
</fC07>
<fC07 i1="16" i2="X" l="FRE"><s0>Pathologie du foie</s0>
<s5>16</s5>
</fC07>
<fC07 i1="16" i2="X" l="ENG"><s0>Hepatic disease</s0>
<s5>16</s5>
</fC07>
<fC07 i1="16" i2="X" l="SPA"><s0>Hígado patología</s0>
<s5>16</s5>
</fC07>
<fC07 i1="17" i2="X" l="FRE"><s0>Immunodéficit</s0>
<s5>18</s5>
</fC07>
<fC07 i1="17" i2="X" l="ENG"><s0>Immune deficiency</s0>
<s5>18</s5>
</fC07>
<fC07 i1="17" i2="X" l="SPA"><s0>Inmunodeficiencia</s0>
<s5>18</s5>
</fC07>
<fC07 i1="18" i2="X" l="FRE"><s0>Immunopathologie</s0>
<s5>19</s5>
</fC07>
<fC07 i1="18" i2="X" l="ENG"><s0>Immunopathology</s0>
<s5>19</s5>
</fC07>
<fC07 i1="18" i2="X" l="SPA"><s0>Inmunopatología</s0>
<s5>19</s5>
</fC07>
<fN21><s1>237</s1>
</fN21>
<fN44 i1="01"><s1>OTO</s1>
</fN44>
<fN82><s1>OTO</s1>
</fN82>
</pA>
</standard>
<server><NO>PASCAL 14-0190715 INIST</NO>
<ET>Vaccination coverage against hepatitis A and B viruses, Streptococcus pneumoniae, seasonal flu, and A(H1N1)2009 pandemic influenza in HIV-infected patients</ET>
<AU>VALOUR (Florent); COTTE (Laurent); VOIRIN (Nicolas); GODINOT (Matthieu); ADER (Florence); FERRY (Tristan); VANHEMS (Philippe); CHIDIAC (Christian)</AU>
<AF>Infectious Diseases Department, Hospices Civils de Lyon/Lyon/France (1 aut., 2 aut., 4 aut., 5 aut., 6 aut., 8 aut.); INSERM U1111, International Center for Research in Infectiology/Lyon/France (1 aut., 5 aut., 6 aut., 8 aut.); Université Claude Bernard Lyon 1/Lyon/France (1 aut., 3 aut., 5 aut., 6 aut., 7 aut., 8 aut.); INSERM U1052/Lyon/France (2 aut.); Department of Hygiene and Epidemiology, Hospices Civils de Lyon/Lyon/France (3 aut., 7 aut.)</AF>
<DT>Publication en série; Niveau analytique</DT>
<SO>Vaccine; ISSN 0264-410X; Coden VACCDE; Royaume-Uni; Da. 2014; Vol. 32; No. 35; Pp. 4558-4564; Bibl. 42 ref.</SO>
<LA>Anglais</LA>
<EA>Background: Several vaccines are recommended in HIV-infected patients due to an increased risk of vaccine-preventable infections, severe forms of the disease, or shared transmission routes. Few data are available regarding vaccination coverage and its determinants in this population. Methods: A cross-sectional study was performed in HIV-infected patients included in a hospital-based cohort in 2011. Vaccination coverage against hepatitis A virus (HAV), hepatitis B virus (HBV), seasonal and A(H1N1)2009 pandemic influenza, and invasive pneumococcal diseases (IPD) were recorded. Factors associated with vaccination were assessed by multivariate logistic regression. Results: 2467 patients were included (median age: 47 years; male gender 71.5%; men having sex with men (MSM): 43.9%; CDC stage C: 24.3%; HBV and/or hepatitis C virus co-infection: 14.4%). Median duration of HIV infection was 10 years and 93.1% of patients received combination antiretroviral therapy. At baseline, the median CD4 count was 527 cells/mm<sup>3</sup>
 and HIV viral load was <50 copies/mL in 83.3% of cases. Vaccination coverage for HBV, HAV, seasonal influenza, A(H1N1)2009 pandemic influenza, and IPD were 61.9%, 47.4%, 30.9, 48.3%, and 64.6%, respectively. Factors independently associated with vaccination were a younger (HBV) or an older age (influenza), male gender (HBV, HAV), MSM (HBV), CD4 count >200/mm<sup>3</sup>
 and HIV-RNA <50 copies/mL (IPD, influenza), longer duration of HIV infection (IPD, influenza), and follow-up by an experienced physician (HBV, IPD). Conclusions: Vaccination coverage remained insufficient for all vaccine-preventable infections investigated in this study. Determinants for vaccination were largely not evidence-based, and efforts should be focused on improving physicians' knowledge about guidelines.</EA>
<CC>002A05F04; 002B05C02G; 002A05B15</CC>
<FD>Streptococcus B; Streptococcus pneumoniae; Virus grippal A; Virus immunodéficience humaine; Couverture vaccinale; Grippe A; SIDA; Virus hépatite B; Pneumococcie; Hépatite virale B; Hépatite virale A</FD>
<FG>Streptococcaceae; Micrococcales; Bactérie; Influenzavirus A; Orthomyxoviridae; Virus; Lentivirus; Retroviridae; Virose; Infection; Orthohepadnavirus; Hepadnaviridae; Streptococcie; Bactériose; Pathologie de l'appareil digestif; Pathologie du foie; Immunodéficit; Immunopathologie</FG>
<ED>Streptococcus B; Streptococcus pneumoniae; Influenza A virus; Human immunodeficiency virus; Vaccination coverage; Influenza A; AIDS; Hepatitis B virus; Pneumococcal infection; Viral hepatitis B; Viral hepatitis A</ED>
<EG>Streptococcaceae; Micrococcales; Bacteria; Influenzavirus A; Orthomyxoviridae; Virus; Lentivirus; Retroviridae; Viral disease; Infection; Orthohepadnavirus; Hepadnaviridae; Streptococcal infection; Bacteriosis; Digestive diseases; Hepatic disease; Immune deficiency; Immunopathology</EG>
<SD>Streptococcus B; Streptococcus pneumoniae; Influenza A virus; Human immunodeficiency virus; Cobertura de vacunación; Gripe A; SIDA; Hepatitis B virus; Neumococia; Hepatitis vírica B; Hepatitis vírica A</SD>
<LO>INIST-20289.354000150336410280</LO>
<ID>14-0190715</ID>
</server>
</inist>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/PandemieGrippaleV1/Data/PascalFrancis/Corpus

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000065 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Corpus/biblio.hfd -nk 000065 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    PandemieGrippaleV1
   |flux=    PascalFrancis
   |étape=   Corpus
   |type=    RBID
   |clé=     Pascal:14-0190715
   |texte=   Vaccination coverage against hepatitis A and B viruses, Streptococcus pneumoniae, seasonal flu, and A(H1N1)2009 pandemic influenza in HIV-infected patients
}}

This area was generated with Dilib version V0.6.34.
Data generation: Wed Jun 10 11:04:28 2020. Site generation: Sun Mar 28 09:10:28 2021

	Serveur d'exploration sur les pandémies grippales
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration sur les pandémies grippales

Vaccination coverage against hepatitis A and B viruses, Streptococcus pneumoniae, seasonal flu, and A(H1N1)2009 pandemic influenza in HIV-infected patients

Vaccination coverage against hepatitis A and B viruses, Streptococcus pneumoniae, seasonal flu, and A(H1N1)2009 pandemic influenza in HIV-infected patients

Source :

Descripteurs français

English descriptors

Abstract

Notice en format standard (ISO 2709)

Format Inist (serveur)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri